Matthew Durdy, CEO, Cell and Gene Therapy Catapult, London, UK, provides an overview of the current state of the cell and gene therapies industry in the UK and outlines some of the key areas of ongoing development. He highlights the research and investment in chimeric antigen receptor (CAR) T-cell therapies, gene therapies, RNA-based therapies, as well as non-viral gene delivery technologies. Cell-delivered therapeutics utilizing induced pluripotent stem cell (iPSC) technology to deliver gene therapies to patients are currently under investigation. This interview took place at the Advanced Therapies Congress & Expo 2021.
The current landscape of advanced therapies in the UK
Теги
Speaker: Matthew DurdyInstitution: Cell and Gene Therapy CatapultEvent: Advanced Therapies 2021Format: InterviewSpecialty: GeneralTechnology: Cell TherapyTechnology: CAR T-cell TherapyTechnology: Gene TherapyTechnology: Induced Pluripotent Stem CellsTechnology: Stem CellsSubject: GeneralField: ManufacturingField: TreatmentField: PerspectivesRNA therapyTechnology: Non-Viral Gene DeliveryiPSCscell-delivered therapeutics